Investigating how natural killer cell-derived vesicles can kill multiple myeloma cells
Molecular Characterization of Anti-Tumor Activity Mediated by Extracellular Vesicles Derived from Natural Killer Cells
This study is looking at how tiny particles from special immune cells can help fight multiple myeloma, especially in patients who have been affected by harmful substances like Agent Orange, with the hope of finding new ways to treat this cancer while protecting healthy cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Louis VA Medical Center NIH-funded |
| Lab location | 1 site (St. Louis, UNITED STATES) |
| Project ID | NIH-11098534 on NIH RePORTER |
What this research studies
This research focuses on understanding how extracellular vesicles derived from natural killer (NK) cells can target and kill multiple myeloma (MM) cells. The study aims to explore the mechanisms by which these vesicles operate, particularly in patients who have been exposed to harmful substances like Agent Orange. By utilizing a unique NK cell line developed in the lab, the research will assess the effectiveness of these vesicles in destroying cancer cells while sparing normal cells. This approach could lead to new treatment options for patients with relapsed or refractory MM.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with multiple myeloma, particularly those who are relapsed or refractory to current therapies.
Not a fit: Patients with early-stage multiple myeloma who are responding well to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with multiple myeloma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using NK cell therapies for cancer treatment, indicating that this approach could be a viable option for multiple myeloma.
Where this research is happening
St. Louis, UNITED STATES
- St. Louis VA Medical Center — St. Louis, United States (Active)
Researchers
- Principal investigator: Kornbluth, Jacki — St. Louis VA Medical Center
- Study coordinator: Kornbluth, Jacki
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.